ArticleBritish journal of pharmacology2008
The alpha1L-adrenoceptor is an alternative phenotype of the alpha1A-adrenoceptor.
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- GPCR theme editorial.British journal of pharmacology · 2009Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite over two decades of research, the molecular identity of the alpha1L-adrenoceptor phenotype has remained elusive. In this issue of the BJP, Gray et al. (2008) provide persuasive evidence that the in vivo alpha1L-adrenoceptor phenotype requires the expression of the alpha1A-adrenoceptor gene. They have shown that in mice lacking the functional alpha1A-adrenoceptor gene, alpha1L-mediated responses to noradrenaline in prostate smooth muscle are substantially attenuated. These findings support earlier evidence that the alpha(1L)-adrenoceptor profile represents a functional phenotype of the alpha(1A)-adrenoceptor gene product, but additional cell background-dependent factors must act in concert with the alpha(1A)-adrenoceptor protein to determine whether an alpha(1L)- or a classical alpha(1A)-adrenoceptor profile is expressed. The challenge remains to establish the nature of these cellular factors and the mechanism(s) by which they influence G-protein-coupled receptor pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.